NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (
NASDAQNEO), a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer PatientsPairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum
NeoGenomics Announces Chief Executive Officer Succession
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (
NASDAQNEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time.
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Chris Smith, Chief Executive Officer, will deliver a presentation followed by Q&A on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET.
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, announced the recent publication of a new study in ESMO Open, demonstrating how circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) may enable earlier identification of disease recurrence for high-risk melanoma patients.
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10. The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel.
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients.
Felicia Williams Joins NeoGenomics Board of Directors
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors.
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City.
NeoGenomics Reports Third Quarter 2024 Results
NeoGenomics, Inc. (
NASDAQNEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024.
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, today announced that the New York State Department of Health (NYSDOH) has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE® DNA & RNA Lung, allowing for immediate commercial access in the state of New York. These next-generation sequencing (NGS) tests deliver better diagnostic value and cost-effectiveness than single gene testing and direct the first-line treatment of diverse solid tumors, including non-small cell lung cancer.
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, today issued the following statement in response to inquiries:
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438). NeoGenomics' data offers key insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusing on their role in early diagnosis and treatment optimization.
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, will attend the Morgan Stanley 22nd Annual Global Healthcare Conference. Chris Smith, Chief Executive Officer, Jeff Sherman, Chief Financial Officer, and Warren Stone, Chief Commercial Officer, will participate in an in-person fireside chat on Friday, Sept. 6, 2024, at 10:45 a.m. ET in New York City.
NeoGenomics Reports Second Quarter 2024 Results
NeoGenomics, Inc. (
NASDAQNEO) (the “Company”), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024.
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights.
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in Fort Myers, NeoGenomics serves over 600,000 patients each year and is on a mission to serve one million patients annually by 2028.
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).
NeoGenomics Reports First Quarter 2024 Results
NeoGenomics, Inc. (
NASDAQNEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024.
NeoGenomics Announces Senior Leadership Promotions
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately.
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company management will host a webcast and conference call that morning at 8:30 a.m. Eastern Time to discuss financial results and recent highlights.
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
NeoGenomics, Inc. (
NASDAQNEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5-10 (booth #915), demonstrating its commitment to advancing cancer patient care through innovative research and development initiatives.
